Psychotropic interactions with warfarin

Acta Psychiatrica Scandinavica

Volumn 102, Issue 4, 2000, Pages 250-255

  Sayal, K S ^a,c   Duncan McConnell, D A ^a   McConnell, H W ^b   Taylor, D M ^a  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cytochrome P 450; Drug interactions; Psychotropic drugs; Warfarin

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; CYTOCHROME P450; FLUOXETINE; FLUPHENAZINE; FLUVOXAMINE; GABAPENTIN; HALOPERIDOL; LITHIUM; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; OLANZAPINE; PAROXETINE; PSYCHOTROPIC AGENT; REBOXETINE; SERTINDOLE; SERTRALINE; SULPIRIDE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; WARFARIN;

ANTICOAGULATION; COMORBIDITY; DRUG EXCRETION; DRUG POTENCY; HUMAN; MEDICAL INFORMATION; MEDICAL LITERATURE; MENTAL DISEASE; PRIORITY JOURNAL; REVIEW; STROKE; THROMBOEMBOLISM; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; URINARY EXCRETION;

ANTICOAGULANTS; ANTIDEPRESSIVE AGENTS; CEREBROVASCULAR ACCIDENT; DEPRESSION; DRUG INTERACTIONS; HUMANS; ISOENZYMES; WARFARIN;

EID: 0033798922     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0447.2000.102004250.x     Document Type: Review

References (45)

1. Systematic review of interaction potential of warfarin is needed
2. Selective serotonin reuptake inhibitor-induced disturbances of haemostasis: Mechanisms and therapeutic implications
3. Stereochemical aspects of warfarin drug interactions: Use of a combined pharmacokinetic-pharmacodynamic model
4. Cytochrome. P450 enzymes: Interpretation of their interactions with selective serotonin reuptake inhibitors. Part 1
5. Pharmacokinetics, metabolism and interactions of acid pump inhibitors
6. Metabolic enantiomeric interactions: The inhibition of human (S)-warfarin-7-hydroxylaze by (R)-warfarin
7. Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers
8. Antidepressant interactions with warfarin
9. Fluoxetine: Clinical pharmacology and physiological disposition
10. Fluoxetine-warfarin interaction
11. Fluoxetine drug-drug interactions. II
12. Potential interaction between warfarin sodium and fluoxetine
13. Fluvoxamine, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depressive illness
14. Evaluation of the potential interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin
15. SSRI treatment of depression with comorbid cardiac disease
16. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: Studies of phenytoin p-hydoxylation
17. The effects of sertraline on the pharmacodynamics of warfarin in healthy volunteers
18. Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin
19. Clinical pharmacokinetics of nefazodone
20. Pharmacokinetic and pharmacodynamic evaluation of warfarin and nefazodone coadministration in healthy subjects
21. Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources
22. Venlafaxine: A structurally unique and novel antidepressant
23. Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide
24. Cytochrome P450 isozymes and antiepileptic drug interactions
25. Bulletin of the West Midlands Centre
26. Concomitant administration of mianserin and warfarin
27. Psychiatry, psychopharmacology and P-450s
28. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine
29. Quetiapine: A review of its use in schizophrenia
30. Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: In vivo evidence of the involvement of CYP3A4 for haloperidol metabolism
31. Pharmacokinetic interactions involving clozapine
32. Interactions of benzodiazepines with warfarin
33. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms
34. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole
35. Interaction between chloral hydrate and warfarin
36. Interaction between carbamazepine and warfarin
37. Warfarin-carbamazepine interaction
38. Valproic acid: A reappraisal of its pharmacological properties and clinical efficacy in epilepsy
39. Effect of valproic acid, its saturated metabolites and some structurally related fatty acids on the binding of warfarin and dansylsarcosine to human albumin
40. Hypothesised interaction between valproic acid and warfarin
41. Warfarin effect enhanced by disulfiram
42. Warfarin effect enhanced by disulfiram (Antabuse)
43. Potentiation of anticoagulant effect by disulfiram
44. Phenytoin: Interactions with other drugs. Part 2: Mechanistic aspects
45. Reduction of prothrombin and partial thromboplastin times with trazodone